New MRI dye could sharpen brain scan images

NCT ID NCT07275814

Recruiting now Diagnosis Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 12, 2026 · Updated 18 times

Summary

This study tests a new contrast agent called HRS-9231 for MRI scans of the brain and spine. About 250 adults with known or suspected brain or spine lesions will receive both HRS-9231 and a standard contrast agent (gadobutrol) in random order. The goal is to see if HRS-9231 is as good as or better than the standard agent at making lesions visible on MRI.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOR CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF CENTRAL NERVOUS SYSTEM (CNS) LESIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Henan Provincial People's Hospital
RECRUITING

Zhengzhou, Henan, 450003, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

FOR CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF CENTRAL NERVOUS SYSTEM (CNS) LESIONS FOR CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF CENTRAL NERVOUS SYSTEM (CNS) LESIONS